Mirati Therapeutics, Inc.
MRTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $12,436 | $72,092 | $13,398 | $3,335 |
| % Growth | -82.7% | 438.1% | 301.7% | – |
| Cost of Goods Sold | $600 | $1,781 | $299,349 | $182,866 |
| Gross Profit | $11,836 | -$436,502 | -$285,951 | -$179,531 |
| % Margin | 95.2% | -605.5% | -2,134.3% | -5,383.2% |
| R&D Expenses | $531,627 | $508,594 | $299,349 | $182,866 |
| G&A Expenses | $0 | $136,679 | $83,412 | $42,573 |
| SG&A Expenses | $239,798 | $136,679 | $83,412 | $42,573 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$5,304 | $11,426 | $8,848 |
| Operating Expenses | $771,425 | $645,273 | $382,761 | $33,725 |
| Operating Income | -$759,589 | -$573,181 | -$369,363 | -$222,104 |
| % Margin | -6,108% | -795.1% | -2,756.9% | -6,659.8% |
| Other Income/Exp. Net | $19,230 | -$5,304 | $11,426 | $8,848 |
| Pre-Tax Income | -$740,359 | -$578,485 | -$357,937 | -$213,256 |
| Tax Expense | $508 | $3,299 | -$511 | -$659 |
| Net Income | -$740,867 | -$581,784 | -$357,937 | -$213,256 |
| % Margin | -5,957.4% | -807% | -2,671.6% | -6,394.5% |
| EPS | -13.18 | -11.21 | -7.96 | -5.69 |
| % Growth | -17.6% | -40.8% | -39.9% | – |
| EPS Diluted | -13.18 | -11.21 | -7.96 | -5.69 |
| Weighted Avg Shares Out | 56,232 | 51,883 | 44,988 | 37,468 |
| Weighted Avg Shares Out Dil | 56,232 | 51,883 | 44,988 | 37,468 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,929 | $1,781 | $641 | $249 |
| EBITDA | -$756,660 | -$571,400 | -$368,722 | -$221,855 |
| % Margin | -6,084.4% | -792.6% | -2,752.1% | -6,652.3% |